Evidences of pathogenic function of Th1 cells in RA were contradicted by the lack of efficiency of therapeutic strategy targeting IFNγ (Fontolizumab) initiated in a phase II clinical trial in active RA. This evidence concerns the gene IFNG and rheumatoid arthritis.